Idorsia: Cardiovascular Franchise Momentum and Underappreciated Pipeline Drive Buy Rating and Valuation Upside

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Idorsia Ltd, with a price target of CHF6.00.

Ram Selvaraju has given his Buy rating due to a combination of factors centered on the growing strength of Idorsia’s cardiovascular franchise and its commercial prospects. He highlights that Health Canada’s marketing authorization for aprocitentan in resistant hypertension expands the drug’s geographic footprint and reinforces its clinical relevance in a high‑need patient population. This additional approval, in his view, enhances the asset’s strategic value in North America and increases the likelihood of securing attractive regional or broader commercial partnerships, which could drive incremental revenue.

Ram Selvaraju’s rating is also based on the broader portfolio and valuation upside embedded in his DCF analysis. He points to aprocitentan’s differentiated profile as the first new systemic antihypertensive mechanism in decades, supported by real-world data and inclusion in major U.S. treatment guidelines, as a key long‑term growth driver, particularly once a robust U.S. partnership is in place. Alongside aprocitentan, he sees meaningful contribution from daridorexant and potential optionality from lucerastat, which together underpin his CHF6 per-share target price despite acknowledged clinical, regulatory, and partnership execution risks. Overall, he believes the current share price does not fully reflect the risk‑adjusted value of these assets, justifying a Buy recommendation.

According to TipRanks, Selvaraju is a 5-star analyst with an average return of 25.7% and a 55.98% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Vanda, Anavex Life Sciences, and Genmab.